Bevantolol

Bevantolol (INN) was a drug candidate for angina and hypertension that acted as both a beta blocker and a calcium channel blocker.^[1][2] It was discovered and developed by Warner-Lambert^[3] but in January 1989 the company announced that it had withdrawn the New Drug Application; the company's chairman said: "Who needs the 30th beta blocker?"^[4] As of 2016^[update] it wasn't marketed in the US, UK, or Europe and the authors of a Cochrane review could find no product monograph for it.^[5]

Bevantolol

Clinical data
AHFS/Drugs.com	International Drug Names
Routes of administration	Oral
ATC code	C07AB06 (WHO)
Identifiers
IUPAC name (RS)-[2-(3,4-dimethoxyphenyl)ethyl][2-hydroxy-3-(3-methylphenoxy)propyl]amine
CAS Number	59170-23-9 Y
PubChem CID	2372
DrugBank	DB01295 Y
ChemSpider	2282 Y
UNII	34ZXW6ZV21
ChEBI	CHEBI:238698 Y
ChEMBL	ChEMBL314010 Y
CompTox Dashboard (EPA)	DTXSID70860597
Chemical and physical data
Formula	C20H27NO4
Molar mass	345.439 g·mol−1
3D model (JSmol)	Interactive image
Chirality	Racemic mixture
SMILES O(c1ccc(cc1OC)CCNCC(O)COc2cc(ccc2)C)C
InChI InChI=1S/C20H27NO4/c1-15-5-4-6-18(11-15)25-14-17(22)13-21-10-9-16-7-8-19(23-2)20(12-16)24-3/h4-8,11-12,17,21-22H,9-10,13-14H2,1-3H3 Y Key:HXLAFSUPPDYFEO-UHFFFAOYSA-N Y
(verify)